393 related articles for article (PubMed ID: 30981113)
1. Synthesis, and evaluation of in vitro and in vivo anticancer activity of 14-substituted oridonin analogs: A novel and potent cell cycle arrest and apoptosis inducer through the p53-MDM2 pathway.
Shen QK; Deng H; Wang SB; Tian YS; Quan ZS
Eur J Med Chem; 2019 Jul; 173():15-31. PubMed ID: 30981113
[TBL] [Abstract][Full Text] [Related]
2. Design and synthesis of novel oridonin analogues as potent anticancer agents.
Shen QK; Chen ZA; Zhang HJ; Li JL; Liu CF; Gong GH; Quan ZS
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):324-333. PubMed ID: 29303372
[TBL] [Abstract][Full Text] [Related]
3. Oridonin derivatives as potential anticancer drug candidates triggering apoptosis through mitochondrial pathway in the liver cancer cells.
Luo D; Yi Y; Peng K; Liu T; Yang J; Liu S; Zhao W; Qu X; Yu W; Gu Y; Wan S
Eur J Med Chem; 2019 Sep; 178():365-379. PubMed ID: 31200238
[TBL] [Abstract][Full Text] [Related]
4. Novel anticancer oridonin derivatives possessing a diazen-1-ium-1,2-diolate nitric oxide donor moiety: Design, synthesis, biological evaluation and nitric oxide release studies.
Xu S; Wang G; Lin Y; Zhang Y; Pei L; Yao H; Hu M; Qiu Y; Huang Z; Zhang Y; Xu J
Bioorg Med Chem Lett; 2016 Jun; 26(12):2795-2800. PubMed ID: 27158140
[TBL] [Abstract][Full Text] [Related]
5. Oridonin induces Mdm2-p60 to promote p53-mediated apoptosis and cell cycle arrest in neuroblastoma.
Zhu HQ; Zhang C; Guo ZY; Yang JM; Guo JH; Chen C; Yao QH; Liu F; Zhang QW; Gao FH
Cancer Med; 2019 Sep; 8(11):5313-5326. PubMed ID: 31339234
[TBL] [Abstract][Full Text] [Related]
6. A Novel Potent Anticancer Compound Optimized from a Natural Oridonin Scaffold Induces Apoptosis and Cell Cycle Arrest through the Mitochondrial Pathway.
Xu S; Yao H; Luo S; Zhang YK; Yang DH; Li D; Wang G; Hu M; Qiu Y; Wu X; Yao H; Xie W; Chen ZS; Xu J
J Med Chem; 2017 Feb; 60(4):1449-1468. PubMed ID: 28165738
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and in vitro and in vivo antitumour activity of 3-benzylideneindolin-2-one derivatives, a novel class of small-molecule inhibitors of the MDM2-p53 interaction.
Zheng GH; Shen JJ; Zhan YC; Yi H; Xue ST; Wang Z; Ji XY; Li ZR
Eur J Med Chem; 2014 Jun; 81():277-88. PubMed ID: 24852275
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and biological evaluation of novel pyrrolidone-based derivatives as potent p53-MDM2 inhibitors.
Si D; Luo H; Zhang X; Yang K; Wen H; Li W; Liu J
Bioorg Chem; 2021 Oct; 115():105268. PubMed ID: 34426149
[TBL] [Abstract][Full Text] [Related]
9. Synthesis of Oridonin Derivatives via Mizoroki-Heck Reaction and Click Chemistry for Cytotoxic Activity.
Hou W; Fan Q; Su L; Xu H
Anticancer Agents Med Chem; 2019; 19(7):935-947. PubMed ID: 30657049
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and biological evaluation of imidazoline derivatives as p53-MDM2 binding inhibitors.
Hu C; Li X; Wang W; Zhang L; Tao L; Dong X; Sheng R; Yang B; Hu Y
Bioorg Med Chem; 2011 Sep; 19(18):5454-61. PubMed ID: 21855354
[TBL] [Abstract][Full Text] [Related]
11. Novel antitumor compound optimized from natural saponin Albiziabioside A induced caspase-dependent apoptosis and ferroptosis as a p53 activator through the mitochondrial pathway.
Wei G; Sun J; Hou Z; Luan W; Wang S; Cui S; Cheng M; Liu Y
Eur J Med Chem; 2018 Sep; 157():759-772. PubMed ID: 30142612
[TBL] [Abstract][Full Text] [Related]
12. Identification of new potent anticancer derivatives through simplifying the core structure and modification on their 14- hydroxyl group from oridonin.
Liu J; Xie S; Shao X; Xue S; Du P; Wu H; Xu S; Chen ZS; Yang DH; Xu J; Yao H
Eur J Med Chem; 2022 Mar; 231():114155. PubMed ID: 35121201
[TBL] [Abstract][Full Text] [Related]
13. DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties.
Soares J; Espadinha M; Raimundo L; Ramos H; Gomes AS; Gomes S; Loureiro JB; Inga A; Reis F; Gomes C; Santos MMM; Saraiva L
Mol Oncol; 2017 Jun; 11(6):612-627. PubMed ID: 28296148
[TBL] [Abstract][Full Text] [Related]
14. Identification of a new class of natural product MDM2 inhibitor: In vitro and in vivo anti-breast cancer activities and target validation.
Qin JJ; Wang W; Voruganti S; Wang H; Zhang WD; Zhang R
Oncotarget; 2015 Feb; 6(5):2623-40. PubMed ID: 25739118
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological evaluation of novel Jiyuan Oridonin A-1,2,3-triazole-azole derivatives as antiproliferative agents.
Ke Y; Liang JJ; Hou RJ; Li MM; Zhao LF; Wang W; Liu Y; Xie H; Yang RH; Hu TX; Wang JY; Liu HM
Eur J Med Chem; 2018 Sep; 157():1249-1263. PubMed ID: 30193221
[TBL] [Abstract][Full Text] [Related]
16. The conversion of oridonin to spirolactone-type or enmein-type diterpenoid: synthesis and biological evaluation of ent-6,7-seco-oridonin derivatives as novel potential anticancer agents.
Wang L; Li D; Xu S; Cai H; Yao H; Zhang Y; Jiang J; Xu J
Eur J Med Chem; 2012 Jun; 52():242-50. PubMed ID: 22483090
[TBL] [Abstract][Full Text] [Related]
17. Effective enmein-type mimics of clinical candidate HAO472: Design, synthesis and biological evaluation.
Hu X; Bai Z; Qiao J; Li H; Xu S; Wang X; Xu Y; Xu J; Hua H; Li D
Eur J Med Chem; 2019 Jun; 171():169-179. PubMed ID: 30921757
[TBL] [Abstract][Full Text] [Related]
18. Targeting the MDM2-p53 protein-protein interaction with prenylchalcones: Synthesis of a small library and evaluation of potential antitumor activity.
Brandão P; Loureiro JB; Carvalho S; Hamadou MH; Cravo S; Moreira J; Pereira D; Palmeira A; Pinto M; Saraiva L; Cidade H
Eur J Med Chem; 2018 Aug; 156():711-721. PubMed ID: 30041135
[TBL] [Abstract][Full Text] [Related]
19. Enmein-type diterpenoid analogs from natural kaurene-type oridonin: Synthesis and their antitumor biological evaluation.
Li D; Xu S; Cai H; Pei L; Zhang H; Wang L; Yao H; Wu X; Jiang J; Sun Y; Xu J
Eur J Med Chem; 2013 Jun; 64():215-21. PubMed ID: 23644204
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of novel benzimidazole-2-substituted phenyl or pyridine propyl ketene derivatives as antitumour agents.
Wu LT; Jiang Z; Shen JJ; Yi H; Zhan YC; Sha MQ; Wang Z; Xue ST; Li ZR
Eur J Med Chem; 2016 May; 114():328-36. PubMed ID: 27017265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
